Press Releases

Press Releases concerning clinical trial results are intended to inform interested parties of the advancements of laser technology in process, not to imply new indications for use. Erchonia supports only those indications for use, cleared by the FDA via 510(k).

FDA Clears Erchonia’s New FX635 Laser for Chronic Heel Pain from Plantar Fasciitis

Erchonia today announces the U.S. Food and Drug Administration (FDA) has granted the company 510 (k) clearance to market FX635, its new low level laser for the relief of chronic heel pain from plantar fasciitis. Clearance was based on a double-blind, randomized, multi-site and placebo-controlled clinical trial.  

McKinney, TX (PRWEB) April 22, 2014

Results of Erchonia’s Lunula Laser’s Clinical Trial for the Noninvasive Treatment of Nail Fungus Published in Podiatry Review

Erchonia today announces that the preliminary results of an ongoing clinical trial testing its Lunula laser for the noninvasive treatment of nail fungus have been published in the latest issue of the medical journal Podiatry Review.

Erchonia Expands Presence in Europe with Erchonia Laser Ltd.

McKinney, TX – November 5, 2013 – Erchonia, the global leader in low level laser healthcare applications, today announces the company is expanding with a London-based team, Erchonia Laser Ltd.

Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

Contact: Katie Cycan
Crier Communications
310-274-1072 x 207

Erchonia XLR8 Laser Granted FDA Clearance for Pain Treatment

Harvard Scientists Commend Erchonia for Excellence in Clinical Research for the Zerona Laser

Tuesday, August 6th 2013
In the latest volume of the medical journal, Lasers in Surgery and Medicine, three Harvard scientists concluded that Erchonia’s research for its Zerona low-level laser device has, "set the precedent on how aesthetic devices should be evaluated."
McKinney, TX (PRWEB) August 06, 2013

Erchonia Launches Zerona Model Search

Model Wins a Trip to Florida, $5,000 cash and Stars in Zerona’s 2012 Marketing Campaign